Gout, allopurinol use, and heart failure outcomes

Archives of Internal Medicine

Volumn 170, Issue 15, 2010, Pages 1358-1364

  Thanassoulis, George ^a   Brophy, James M ^a   Richard, Hugues ^a   Pilote, Louise ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL;

AGED; ARTICLE; CANADA; CONTROLLED STUDY; FEMALE; GOUT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALLOPURINOL; CASE-CONTROL STUDIES; FEMALE; GOUT; GOUT SUPPRESSANTS; HEART FAILURE; HUMANS; MALE; PATIENT READMISSION; QUEBEC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77955442528     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.198     Document Type: Article

References (51)

1. Jankowska EA, Ponikowska B, Majda J, et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol. 2007; 115(2):151-155. (Pubitemid 46136516)
2. Niizeki T, Takeishi Y, Arimoto T, et al. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol. 2006;47 (5):219-228. (Pubitemid 46940514)
3. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107(15):1991-1997. (Pubitemid 36506072)
4. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 1991;65(5):245-248.
5. Prasad K, Kalra J, Chan WP, Chaudhary AK. Effect of oxygen free radicals on cardiovascular function at organ and cellular levels. Am Heart J. 1989;117(6): 1196-1202. (Pubitemid 19150746)
6. Ghatak A, Brar MJS, Agarwal A, et al. Oxy free radical system in heart failure and therapeutic role of oral vitamin E. Int J Cardiol. 1996;57(2):119-127. (Pubitemid 26423567)
7. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications [published online ahead of print December 23, 2003]. J Physiol. 2004;555(pt 3):589-606.
8. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114. (Pubitemid 43316063)
9. Kittleson MM, Hare JM. Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. Eur Heart J. 2005;26(15):1458-1460.
10. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900. (Pubitemid 47300913)
11. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104-1110. (Pubitemid 351749228)
12. Amado LC, Saliaris AP, Raju SVY, et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol. 2005;39(3):531-536.
13. Kögler H, Fraser H, McCune S, Altschuld R, Marban E. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res. 2003;59(3):582-592. (Pubitemid 38368674)
14. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marban E, Weiss RG. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol. 2006;290(2):H837-H843.
15. Ukai T, Cheng C-P, Tachibana H, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation. 2001;103(5):750-755. (Pubitemid 32144206)
16. Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 2004;110(15):2175-2179. (Pubitemid 39372497)
17. Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J. 2005;26(15):1544-1550. (Pubitemid 41373497)
18. Minhas KM, Saraiva RM, Schuleri KH, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res. 2006; 98(2):271-279. (Pubitemid 43755359)
19. Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004;95(10):1005-1011. (Pubitemid 39534412)
20. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001; 104(20):2407-2411. (Pubitemid 33108372)
21. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Perez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail. 2006;12(7):491-498. (Pubitemid 44307706)
22. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619-2624. (Pubitemid 34596038)
23. Farquharson CAJ, Butler R, Hill A, Belch JJF, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106 (2):221-226. (Pubitemid 34761303)
24. George J, Carr E, Davies J, Belch JJF, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508-2516. (Pubitemid 44901524)
25. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart. 2005;91(6):749-753.
26. Hare JM, Mangal B, Brown J, et al; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301-2309. (Pubitemid 351783365)
27. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J. 2003;146(4):581-590.
28. Essebag V, Platt R, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005;5(1):5. doi:10.1186/1471-2288-5-5.
29. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA. Coding accuracy of hospital discharge data for elderly survivors ofmyocardial infarction. Can J Cardiol. 1999;15(11):1277-1282. (Pubitemid 30006767)
30. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol. 1995; 48(8):999-1009.
31. World Health Organization. International Classification of Diseases, Ninth Revision. Geneva, Switzerland: World Health Organization; 1977.
32. Goff DC Jr, Pandey DK, Chan FA, Ortiz C, Nichaman MZ. Congestive heart failure in the United States: is there more than meets the I(CD code)? the Corpus Christi Heart Project. Arch Intern Med. 2000;160(2):197-202. (Pubitemid 30054339)
33. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344-350. (Pubitemid 38944258)
34. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies, III: design options. Am J Epidemiol. 1992;135(9):1042-1050.
35. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984;40(1):63-75.
36. Robins JM, Gail MH, Lubin JH. More on "Biased Selection of Controls for Case-Control Analyses of Cohort Studies." Biometrics. 1986;42(2):293-299.
37. Wacholder S, Gail M, Pee D. Selecting an efficient design for assessing exposure-disease relationships in an assembled cohort. Biometrics. 1991;47(1):63-76.
38. Harrold LR, Saag KG, Yood RA, et al. Validity of gout diagnoses in administrative data. Arthritis Rheum. 2007;57(1):103-108. (Pubitemid 46256731)
39. Breslow NE, Day NE. The Analysis of Case-Control Studies. Vol 1. Lyon, France: International Agency for Research on Cancer (IARC); 1980. IARC Scientific Publication 32.
40. Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc. 1983;78:1-12.
41. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298(22):2634-2643. (Pubitemid 350254955)
42. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554-2560. (Pubitemid 43866389)
43. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
44. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113(11):1424-1433. (Pubitemid 43739439)
45. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002;87(3):229-234. (Pubitemid 34177675)
46. de Jong JW, Schoemaker RG, de Jonge R, et al. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000; 32(11):2083-2089.
47. Ekelund UEG, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res. 1999;85(5):437-445. (Pubitemid 29409620)
48. Saavedra WF, Paolocci N, St. John ME, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res. 2002;90(3):297-304. (Pubitemid 34633931)
49. 2+ cycling proteins and β-adrenergic hyporesponsiveness in heart failure [published online ahead of print October 27, 2006]. Am J Physiol Heart Circ Physiol. 2007;292(3):H1328-H1335.
50. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38 (5):1101-1106. (Pubitemid 34252813)
51. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-932.